The Cognitive Impairment drugs in development market research report provides comprehensive information on the therapeutics under development for Cognitive Impairment, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Cognitive Impairment. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Cognitive Impairment and features dormant and discontinued products.
GlobalData tracks 118 drugs in development for Cognitive Impairment by 93 companies/universities/institutes. The top development phase for Cognitive Impairment is preclinical with 52 drugs in that stage. The Cognitive Impairment pipeline has 108 drugs in development by companies and ten by universities/ institutes. Some of the companies in the Cognitive Impairment pipeline products market are: Dart NeuroScience, CuraSen Therapeutics and ProNeurogen.
The key targets in the Cognitive Impairment pipeline products market include Amyloid Beta A4 Protein (ABPP or APPI or Alzheimer Disease Amyloid Protein or Amyloid Precursor Protein or Amyloid Beta Precursor Protein or Cerebral Vascular Amyloid Peptide or Prea4 or Protease Nexin II or APP), Glutamate Ionotropic Receptor NMDA Type Subunit (NMDAR or GRIN), and Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7).
The key mechanisms of action in the Cognitive Impairment pipeline product include Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) Agonist with four drugs in Phase I. The Cognitive Impairment pipeline products include nine routes of administration with the top ROA being Oral and 12 key molecule types in the Cognitive Impairment pipeline products market including Small Molecule, and Synthetic Peptide.
Cognitive Impairment overview
Cognitive impairment is a condition characterized by a decline in cognitive functions, such as memory, attention, and problem-solving skills. It can range from mild to severe and may result from various causes, including aging, neurodegenerative diseases (like Alzheimer’s), vascular disorders, traumatic brain injuries, infections, medication side effects, mental health issues, nutritional deficiencies, or environmental factors. Symptoms can include memory loss, confusion, difficulty concentrating, and impaired judgment. Diagnosis involves a thorough assessment, and management strategies depend on the underlying cause, ranging from lifestyle modifications and medication to therapeutic interventions. Early detection and intervention are crucial for effective management and improved quality of life.
For a complete picture of Cognitive Impairment’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
